Army Times on MSN1d
DOD commits $9.8 million to study psychedelics for active-duty troopsDuring one study, physicians at Walter Reed plan to give the psychedelic drug MDMA to up to 450 active-duty soldiers with ...
According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...
A 60-patient, randomized, double-blind, placebo-controlled phase I clinical study of VAS101 (topical curcumin gel) in osteoarthritis (OA) is underway. The study is being conducted at Clinical Research ...
Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...
An expert discusses how CheckMate 274 is a phase 3, randomized, double-blind trial evaluating adjuvant nivolumab vs placebo ...
In the study, treatment with AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6), led to faster radiographic fusion and a higher fusion success rate, as well as greater improvements in ...
Natural products industry companies share overviews on the latest science on their branded ingredients and formulations to ...
Galcanezumab provided greater reductions in migraine frequency, resulting in a shift from chronic to episodic migraine over a 12-month period compared with placebo.
By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback